Foundation Medicine (FMI) Prelim. Q4 Revenue Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St falls as oil ticks up, yields rise ahead of US-China summit
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
Foundation Medicine Reports Preliminary 2017 Results
January 8, 2018 6:30 AM ESTReports Total Revenue of Approximately $152.9 Million, a 31% Year Over Year Increase; Reports 67,375 Clinical Tests in 2017, a 54% Year Over Year Increase
Increases Biopharma Revenue Approximately 27% Year-Over-Year with New and Expanded Collaborations
Achieves Significant Milestone with FDA Approval and Preliminary National Coverage Determination (NCD) for FoundationOne CDx
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine (NASDAQ: FMI) today announced... More
